申联生物(688098.SH)：艾滋病单克隆抗体等创新药管线由世之源独立运营

Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days [1] - The main business of the company is focused on veterinary biological products, while the innovative drug pipeline, including HIV monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [1]